September 2026 Research Update

This month, the main pattern was that dermatomyositis is being divided into more specific subtypes using a combination of blood antibody tests, skin biopsy markers, and noninvasive imaging of tiny nailfold blood vessels. The studies also showed that dermatomyositis can mimic other autoimmune skin and joint diseases, and that some people may have skin-predominant disease or normal muscle enzymes despite weakness, which can delay correct labeling. Evidence ranged from moderate-sized observational studies to single-patient case reports, so several tools still need validation in broader, real-world settings. [1] [2] [3] [4] [5]

One multicenter study focused on measuring anti-NXP2 antibodies with a lab test that reports an antibody level (not just positive or negative). Higher anti-NXP2 antibody levels tracked with higher inflammation markers and a higher cardiothoracic ratio (a simple measure related to heart size), and antibody levels were higher in those with cancer; levels dropped after immune-suppressing treatment. The same study proposed a scoring system using age at onset, a classic skin sign, muscle blood tests, and cancer status to help tell anti-NXP2-positive disease apart from anti-TIF1-gamma-positive dermatomyositis. [1]

In children, automated nailfold video capillaroscopy (a close-up camera test of the small blood vessels at the base of the fingernail) grouped patients into patterns that differed by diagnosis. A "branched" capillary pattern was enriched in juvenile dermatomyositis and overlap myositis, and most children with anti-TIF1-gamma-positive juvenile dermatomyositis fell into this branched group. Microhemorrhage density (tiny bleeding spots) moved in the same direction as clinician-rated activity and, in a small follow-up group, decreased over about 3 months while capillary density increased after treatment. [3]

A diagnostic accuracy study suggested a skin-biopsy stain for IL-18 can help separate dermatomyositis from cutaneous lupus in some cases. IL-18 staining in skin cells was more common in dermatomyositis than lupus, and a strong full-thickness staining pattern was seen only in dermatomyositis, while complete absence of staining was seen only in lupus. The authors emphasized that the stain is most helpful at the extremes (very strong or completely absent) and still needs to be interpreted alongside clinical and standard biopsy features. [2]

Two case reports illustrated how different subtypes can present in unexpected ways and why antibody testing can matter for correct classification. One man had intensely itchy, psoriasis-like plaques but was ultimately identified as anti-SAE dermatomyositis with mostly skin involvement and minimal muscle symptoms. Another man had anti-MDA5 dermatomyositis that looked like an overlap of several connective tissue diseases, with lupus-like skin findings, inflammatory arthritis, normal creatine kinase despite weakness, and interstitial lung disease on chest scan. [5] [4]

A separate gene-expression analysis using public datasets in juvenile dermatomyositis reported that many neuromuscular junction-related genes differed from healthy controls, and it highlighted MBP and CHRNA1 as potential markers that could separate juvenile dermatomyositis from controls in that dataset. CHRNA1 levels also tracked with muscle and skin disease activity measures, suggesting these gene-activity markers might one day help with monitoring, but the authors noted that independent validation is needed. [6]

Finally, an imaging-based biopsy study used scanning electron microscopy to describe muscle fiber surface patterns across inflammatory muscle diseases, including dermatomyositis. Dermatomyositis samples had more preserved muscle fiber ultrastructure compared with other subtypes, which showed different damage signatures; the authors suggested these patterns could add to understanding of disease differences but require larger validation before they can support routine subtype classification. [7]

A small, single-center series of 17 children with juvenile dermatomyositis reported that muscle MRI was used in selected cases and showed inflammatory changes when performed, supporting its role as one tool clinicians may use when the diagnosis is unclear. The same report showed that standard muscle blood tests were not uniformly abnormal (for example, creatine kinase was elevated in a minority), which helps explain why multiple types of tests are often needed to confirm juvenile dermatomyositis and rule out look-alikes. [8]

For patients and caregivers, these studies mainly provide background on why dermatomyositis diagnosis and subtyping can take time and why clinicians often combine several kinds of information (antibody panels, skin or muscle biopsy interpretation, lung imaging when needed, and sometimes nailfold capillary imaging in children). Some tools, like IL-18 staining on skin biopsy and quantitative antibody-level testing, are closer to clinical use but still have limits and are not definitive on their own, while gene-expression and scanning electron microscopy approaches are earlier-stage and primarily research. What remains uncertain is how well these newer measures perform across diverse clinics and how much they improve day-to-day diagnostic accuracy beyond existing testing.

Across these studies, the clearest pattern was that a rapidly worsening form of interstitial lung disease was the main setting for the most serious outcomes, especially in people with anti-MDA5 antibodies. Several measurable factors at presentation, including a blood clotting marker (D-dimer) and an immune cell count (CD4 T cells), were linked to survival in hospitalized or high-risk groups, but evidence is still limited because most data were retrospective. [9] [10] [11]

In a small adult cohort of anti-MDA5-positive dermatomyositis with interstitial lung disease, higher baseline D-dimer was independently linked with a higher chance of death, while the tissue-damage marker LDH did not stay independently predictive after adjustment. In this study, every person who died met criteria for rapidly progressive interstitial lung disease, and severe infections were described as contributing to deaths. [9]

In hospitalized patients with an acute worsening of dermatomyositis/polymyositis-related interstitial lung disease, in-hospital death was common overall and even more frequent in the anti-MDA5-positive subgroup. Lower CD4 T-lymphocyte counts were the strongest single predictor of death, and pleural effusion, higher neutrophil percentage, and higher C-reactive protein were also part of a predictive model. [10]

In a larger pediatric cohort with juvenile dermatomyositis-related interstitial lung disease, most children reached inactive disease by last follow-up, but deaths occurred in anti-MDA5-positive patients due to rapidly progressive interstitial lung disease within a few months. The authors also developed a risk tool (nomogram) that estimated the chance of reaching inactive disease over 1 to 5 years using clinical features and treatments, with moderate accuracy in internal testing. [11]

One case report showed how anti-MDA5-positive dermatomyositis can initially look like other severe lung problems after surgery, delaying the correct diagnosis until more specialized antibody testing was done. The patient improved after combination immune-suppressing treatments and left the hospital needing supplemental oxygen, but the report cannot show how often this happens or which treatment works best in general. [12]

For patients and caregivers, these papers mainly add context about why some dermatomyositis-related lung disease becomes dangerous quickly: rapidly progressive interstitial lung disease and anti-MDA5 antibodies repeatedly appeared in the sickest groups. They also suggest that certain routine or near-routine tests (such as D-dimer, inflammation markers, and immune cell counts) may help clinicians estimate risk during severe lung flare-ups, but these results come mostly from retrospective studies and need confirmation in other hospitals and populations. [9] [10] [11] [12]

Across these mainly single-patient reports, dermatomyositis (DM) sometimes appeared as a paraneoplastic condition, meaning the immune system activity linked to a cancer may contribute to DM symptoms. A repeated pattern was that steroids and immune treatments alone did not always control muscle or swallowing problems, while improvement was sometimes seen after cancer-directed therapy. Because most evidence here comes from case reports, it cannot show how often this happens or predict outcomes for most people with DM. [13] [14] [15] [16]

In one woman with cervical squamous cell carcinoma, skin symptoms improved first with high-dose steroids, but larger gains in muscle strength and swallowing were described after chemoradiotherapy, alongside tumor regression and falling muscle enzyme levels. The report also noted anti-TIF1-gamma antibodies, a blood marker sometimes discussed in DM in relation to cancer risk. This is a single case, so it cannot tell whether similar improvement would happen for others. [14]

In an elderly man whose DM-like symptoms initially resembled polymyalgia rheumatica, the underlying cancer was metastatic acral melanoma identified after scans and biopsy. After corticosteroids plus targeted melanoma treatment (BRAF/MEK inhibitors), the case report described resolution of muscle symptoms along with a radiology-based tumor response. Because it describes one person, it mainly illustrates how cancer and DM symptoms can overlap rather than providing a typical course. [15]

A separate case report described an 80-year-old man with seronegative DM whose workup found an HPV-related (p16-positive) squamous cell carcinoma in a cervical lymph node, with no detectable primary tumor site. Despite high-dose steroids and intravenous immune globulin (IVIG), he worsened quickly and died about three months after symptoms began, showing that paraneoplastic presentations can be severe and fast-moving in some individuals. The family declined further invasive testing, which limited how much could be confirmed about the cancer source. [13]

One paper combined a DM case with metastatic papillary thyroid carcinoma, a small case series and literature review, and genetic and tissue studies to explore whether thyroid cancer and DM may be linked. DM symptoms (including rash) improved in the featured case after surgical removal of metastatic disease, and a Mendelian randomization analysis suggested a possible direction from thyroid cancer to myositis in one statistical approach but not others, so the overall signal was mixed. Tumor tissue from the DM-associated case had higher TIF-1-gamma staining than tumor tissue from a thyroid cancer patient without DM, which supports (but does not prove) a shared immune target idea. [16]

For patients and caregivers, this set of studies mainly serves as background: it illustrates that, in some people, DM can appear around the same time as a newly recognized cancer, and DM symptoms may sometimes track with how the cancer responds to treatment. It also shows that the cancer linked with DM is not limited to one organ, spanning gynecologic cancer, thyroid cancer, melanoma, and head and neck-related lymph node disease in these reports. What remains uncertain from this evidence is how common any of these patterns are, which people with DM are most affected, and how well specific blood markers (such as anti-TIF1-gamma) predict cancer-related DM across diverse patients.

Across two retrospective juvenile dermatomyositis (childhood dermatomyositis) cohorts and one adult case report, calcinosis (calcium deposits in skin or deeper tissues) was tied to recognizable immune markers, especially anti-NXP2 antibodies. These papers also suggest calcinosis can be persistent once established, with mixed responses over time, and may show different body patterns depending on antibody type. [17] [18] [19]

In a large single-center study from India of 157 children with juvenile dermatomyositis, calcinosis was present in 28% and was linked to delay in diagnosis, lipodystrophy, and anti-NXP2 positivity, while more severe calcinosis was linked to a younger age at disease start. Calcinosis improved in 39% of affected children, while 61% stayed the same or progressed, highlighting that improvement is possible but not the most common outcome in this cohort. [17]

The same pediatric study described different calcinosis patterns by antibody type: anti-TIF1-gamma was linked to more superficial deposits around large joints with skin ulceration, while anti-NXP2 was linked to more extensive or severe calcinosis. A small number of children had calcinosis even without clear skin or muscle symptoms at the time they were assessed, including some who were anti-NXP2 positive. [17]

A smaller Japanese cohort of 36 children found that higher CD8+ T-cell levels (including age-adjusted levels) were seen in those with subcutaneous calcinosis, suggesting immune-cell measurements at diagnosis might relate to calcinosis risk. This study also reported that anti-MDA5 antibodies tracked with interstitial lung disease and higher KL-6 blood levels, showing that different antibodies may point to different complication risks. [18]

One adult case report described a 52-year-old woman with anti-NXP2 positive dermatomyositis who developed rapidly progressive calcinosis within months despite immunosuppressive treatment. In this single patient, intravenous immune globulin did not help, monthly injections of steroid into lesions helped mildly, and tocilizumab provided partial benefit, illustrating how difficult established calcinosis can be to control in some people. [19]

For patients and caregivers, these studies mainly add context about why calcinosis may happen and why it can look and behave differently from person to person. Blood antibody results (such as anti-NXP2, anti-TIF1-gamma, and anti-MDA5) and some immune-cell measurements were linked to specific complication patterns in these cohorts, but they do not predict outcomes with certainty for an individual. The treatment information here is limited because it comes from retrospective reviews and one case report, so it is most useful as background on variability and uncertainty rather than as a guide to what will work for any one patient. [17] [18] [19]

Across two case reports (each describing one person), upadacitinib was used after other treatments had not controlled dermatomyositis or related antisynthetase syndrome symptoms. Both reports described clearer improvement in muscle symptoms and blood muscle markers, while skin disease in one patient improved most after an increase to a higher daily dose. Because these are individual cases and other medicines were used at the same time, it is not possible to know how much of the improvement was due to upadacitinib alone. [20] [21]

In a 33-year-old woman with anti-Jo-1 positive antisynthetase syndrome presenting with a dermatomyositis-like pattern and relapsing muscle inflammation, upadacitinib was increased while intravenous immunoglobulin and glucocorticoids were also adjusted during a flare. The report described sustained symptom and lab control on the higher dose, and later stopping prednisone, but the authors noted the overlap with other treatments limits cause-and-effect conclusions. Flares occurred when upadacitinib was interrupted for fertility treatment and improved after it was restarted, which the authors presented as supportive but still not definitive evidence. [20]

In a 49-year-old woman with anti-TIF1gamma positive dermatomyositis and difficult-to-control skin disease, adding upadacitinib to ongoing prednisolone and mycophenolate mofetil was followed by improved muscle strength, normalized muscle blood tests, and resolution of swallowing difficulty by 4 months. The skin score improved further after the daily dose was increased, with a major skin response reported within 4 weeks and remission maintained at 12 months; repeated cancer surveillance testing was reported as negative during follow-up. Side effects were not described in this report. [21]

For patients and caregivers, these reports are best viewed as early, low-strength evidence about a treatment sometimes tried when standard options have not worked well, including in people with specific antibodies (anti-Jo-1 or anti-TIF1gamma) and problems such as relapsing muscle inflammation, severe skin disease, or swallowing issues. They suggest that responses may differ by organ (for example, muscle vs skin) and that stopping a medicine for other life reasons may complicate symptom control, but neither report can show what would happen in most people. Larger studies are still needed to clarify how effective and safe upadacitinib is in dermatomyositis and related conditions, and how much benefit comes from upadacitinib versus other medicines used at the same time. [20] [21]

Across this group of papers, a clear pattern is that dermatomyositis can come with important health issues beyond skin and muscle symptoms, including severe immune over-activation, other organ complications, and day-to-day quality of life burdens. The strongest evidence here comes from observational studies and a systematic review, while several reports describe single patients and cannot show how often these issues happen. Overall, the research highlights both medical complications (like inflammation affecting blood, kidneys, heart, eyes, or thyroid) and practical challenges (like food, transportation, and health literacy barriers) that can shape living with the disease. [22] [23] [24] [25] [26] [27]

A systematic review of reported cases of macrophage activation syndrome in juvenile dermatomyositis (a dangerous, uncontrolled inflammation syndrome) found it often appeared within 3 months of juvenile dermatomyositis starting, and sometimes right at the beginning. The review also noted that doctors used very different diagnostic approaches across reports, and deaths still occurred, showing this complication can be life-threatening even with treatment. Anti-MDA5 was the most frequently reported antibody in these cases, but the review emphasized the overall evidence base is limited and inconsistent. [22]

In adults with idiopathic inflammatory myopathies (a group that includes dermatomyositis), thyroid disorders were common in a single-center retrospective study. People with thyroid disorders more often had swallowing-related esophagus involvement and more bone thinning and fractures, and they reported worse bodily pain on a quality-of-life questionnaire. The study also found higher lifetime exposure to steroid medicines in those with thyroid disorders, but it could not prove what caused what. [23]

Quality of life is also shaped by social needs that can make care harder to access. In a caregiver survey from an urban pediatric rheumatology clinic that included juvenile dermatomyositis, 39% reported at least one unmet social need, and barriers were especially frequent in Spanish-speaking, Hispanic/Latino, and publicly insured or uninsured families. Food insecurity, transportation problems, housing instability, and difficulty reading health materials were more common in families living in more disadvantaged neighborhoods. [24]

Two studies focused on other real-world complications in children and adults. A UK population-based cohort study found children with juvenile dermatomyositis were, on average, shorter at diagnosis than healthy peers, with some evidence of catch-up growth later, while weight patterns were broadly similar to controls; results were less consistent in juvenile dermatomyositis than in juvenile arthritis because the juvenile dermatomyositis group was smaller. Separately, an eye-related case report described a woman with long-standing dermatomyositis who developed an extra row of eyelashes (distichiasis) without symptoms or corneal damage, and the authors could not confirm dermatomyositis as the cause. [25] [26]

A separate case report described a person with mixed connective tissue disease who developed dermatomyositis features and then a severe kidney complication (scleroderma renal crisis) with thrombotic microangiopathy and fatal heart complications. Imaging showed widespread scarring in the heart muscle, and the patient died despite multiple treatments, illustrating that overlapping autoimmune diseases can sometimes involve multiple organs and progress quickly. Because this is a single case, it cannot tell how common these events are. [27]

For patients and caregivers, this set of studies mainly adds context about the kinds of complications and life impacts that may come up alongside dermatomyositis, rather than changing care right now. The most immediate takeaways are awareness-oriented: rare but severe immune complications have been reported in children; thyroid problems are common in adults with inflammatory muscle diseases and were linked to more pain and swallowing involvement in one center; and many families face practical barriers that can affect day-to-day wellbeing and access to care. What remains uncertain is how often several of these issues occur in dermatomyositis specifically (especially when evidence comes from case reports, small juvenile dermatomyositis samples, or mixed-diagnosis clinics) and which factors most strongly drive risk.